- Home
- MRK
as 05-30-2025 2:39pm EST
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | KENILWORTH |
| Market Cap: | 218.2B | IPO Year: | N/A |
| Target Price: | $113.71 | AVG Volume (30 days): | 14.2M |
| Analyst Decision: | Buy | Number of Analysts: | 15 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 6.88 | EPS Growth: | 667.14 |
| 52 Week Low/High: | $73.31 - $134.63 | Next Earning Date: | 04-24-2025 |
| Revenue: | $63,922,000,000 | Revenue Growth: | 4.10% |
| Revenue Growth (this year): | 2.42% | Revenue Growth (next year): | 5.64% |
Latest Merck & Company Inc. (new) News
MRK Breaking Stock News: Dive into MRK Ticker-Specific Updates for Smart Investing
Investor's Business Daily
6 hours ago
Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failure
Business Wire
7 hours ago
Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor, Shows Antitumor Activity in Phase 1 Trial of Patients With Advanced Colorectal Cancer and Non-Small Cell Lung Cancer Whose Tumors Harbor KRAS G12C Mutations
Business Wire
7 hours ago
Merck’s Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory DLBCL in Phase 2 Portion of waveLINE-003 Trial
StockStory
14 hours ago
2 Cash-Producing Stocks for Long-Term Investors and 1 to Steer Clear Of
Insider Monkey
a day ago
Merck KGaA (MKGAF) Files for Global Approval of Pimicotinib After Positive Phase III TGCT Results
Zacks
a day ago
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
MT Newswires
a day ago
Merck Withdraws Biologics License Application for Patritumab Deruxtecan
Yahoo Finance
a day ago
Moderna suffers a $750 million loss from NIH funding cut
Compare MRK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MRK Merck & Company Inc. (new) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.